Evidence map›Paper›PMID 29356823›Full record

Observational studyJAMA neurology2018

Association of β-Amyloid and Apolipoprotein E ε4 With Memory Decline in Preclinical Alzheimer Disease.

Yen Ying Lim, Pawel Kalinowski, Robert H Pietrzak, Simon M Laws, Samantha C Burnham, David Ames, Victor L Villemagne, Christopher J Fowler, Stephanie R Rainey-Smith, Ralph N Martins and 3 more

Open access · bronzeAbstract readObservational Study
In one paragraph

Observational study in JAMA neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 2 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Differential Effects ofNeurology · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Yen Ying LimThe Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.
Pawel KalinowskiCogState, Ltd, Melbourne, Victoria, Australia.
Robert H PietrzakDepartment of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.
Simon M LawsCentre of Excellence for Alzheimer's Disease Research and Care, Edith Cowan University, Joondalup, Western Australia, Australia.
Samantha C BurnhamCommonwealth Scientific and Industrial Research Organisation Preventative Health National Research Flagship, Australian e-Health Research Centre, Brisbane, Queensland, Australia.
David AmesAcademic Unit for Psychiatry of Old Age, St Vincent's Health, University of Melbourne, Kew, Victoria, Australia.
Victor L VillemagneThe Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.
Christopher J FowlerThe Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.
Stephanie R Rainey-SmithCentre of Excellence for Alzheimer's Disease Research and Care, Edith Cowan University, Joondalup, Western Australia, Australia.
Ralph N MartinsCentre of Excellence for Alzheimer's Disease Research and Care, Edith Cowan University, Joondalup, Western Australia, Australia.
Christopher C RoweDepartment of Nuclear Medicine and Centre for PET (Positron Emission Tomography), Austin Health, Heidelberg, Victoria, Australia.
Colin L MastersThe Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.
Paul T MaruffThe Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.
University of Melbourne · AUEdith Cowan University · AUAustin Health · AUAustralian e-Health Research Centre · AUFlorey Institute of Neuroscience and Mental Health · AUYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Older age, high levels of β-amyloid (Aβ), and the presence of the apolipoprotein E (APOE) ε4 allele are risk factors for Alzheimer disease (AD). However, the extent to which increasing age, Aβ, and ε4 are associated with memory decline remains unclear, and the age at which memory decline begins for Aβ-positive ε4 carriers and noncarriers has not been determined. Objective: To determine the association of age, Aβ level, and APOE ε4 with memory decline in a large group of cognitively healthy older adults. Design, Setting, and Participants: This longitudinal observational study included cognitively healthy older adults (age >60 years) enrolled in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study from March 31, 2006, through March 31, 2017; of 1583 individuals enrolled, 1136 refused or were excluded owing to other criteria (eg, having mild cognitive impairment or AD). Participants underwent Aβ imaging in research clinics in Perth and Melbourne and more than 72 months of follow-up (at 18-month intervals). The association of age with memory was fitted to a quadratic model. Age was treated as a continuous, time-dependent variable. Exposures: β-Amyloid imaging using positron emission tomography, genotyping for APOE ɛ4, and longitudinal neuropsychological assessments of episodic memory during the 72-month follow-up. Main Outcomes and Measures: Episodic memory composite score. Results: Of the 447 participants, 203 (45.4%) were men and 244 (54.6%) were women; mean (SD) age was 72.5 (6.6) years. Equal proportions of female participants were observed in each Aβ-ɛ4 group (24 of 51 Aβ-positive ε4 noncarriers [47.1%] ; 35 of 64 Aβ-negative ε4 carriers [54.7%]; 40 of 72 Aβ-positive ε4 carriers [55.6%]; and 145 of 260 Aβ-negative ε4 noncarriers [55.8%]). Adults with Aβ findings (mean [SD] age, 74.4 [6.8] years) were approximately 4 years older than those negative for Aβ (mean [SD] age, 69.8 [6.1] years). Memory decline diverged significantly from Aβ-negative ɛ4 noncarriers at an earlier age in Aβ-positive ɛ4 carriers (64.5 years) than in Aβ-positive ɛ4 noncarriers (76.5 years), such that by 85 years of age, Aβ-positive ε4 carriers performed approximately 1.5 SD units worse on the episodic memory composite than Aβ-negative ε4 noncarriers and approximately 0.8 SD units worse than Aβ-positive ε4 noncarriers. Memory performance of Aβ-negative ɛ4 carriers did not differ from that of the Aβ-negative ɛ4 noncarriers (estimate [SE], 0.001 [0.001]; t = 0.526; P = .77). Conclusions and Relevance: Prior work has shown that Aβ and ε4 combine to influence memory decline in nondemented older adults. Results of this study indicate that increasing age may further exacerbate these effects. The estimates provided may be used to determine the risk of memory decline associated with Aβ and ε4 at each age.

Indexed as

Alzheimer DiseaseAgedAged, 80 and overAmyloid beta-PeptidesApolipoprotein E4Asymptomatic DiseasesDisease ProgressionFemaleHumansLongitudinal StudiesMaleMemory DisordersMiddle AgedNeuropsychological TestsPositron-Emission TomographyTime FactorsAmyloid beta-PeptidesApolipoprotein E4

Identifiers

PMID29356823
PMCPMC5933393
OpenAlexW2787153892

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.